​


Sources
GLP-1 Drugs Show Beneficial Effects Across Multiple Cancer Types, New Research Suggests
Bariatric Surgery Shows Greater Long-Term Cardiovascular Benefits Than GLP-1 Weight-Loss Medications
Eli Lilly's Foundayo demonstrates cardiovascular safety in ACHIEVE-4 diabetes trial
Novo Nordisk shifts marketing of GLP-1 drugs from obesity 'patients' to lifestyle 'customers'
Man who weighed 49 stone loses 32 stone after doctor's warning during heart surgery
Eli Lilly Opens Limited Early Access Program for Experimental Obesity Drug Retatrutide
UK becomes first European country to approve Eli Lilly's once-daily weight loss pill Foundayo
Novo Nordisk CEO says weight-loss pills could capture 50% of obesity market by 2030
AstraZeneca's experimental obesity pill achieves 10.5% weight loss in phase II trial
CVS Health Restores Coverage of Eli Lilly's Zepbound and Adds New Obesity Pill to Drug Plans
Comments (0)
Loading comments...